445 related articles for article (PubMed ID: 31508364)
1. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.
Thomas R; Weihua Z
Front Oncol; 2019; 9():800. PubMed ID: 31508364
[TBL] [Abstract][Full Text] [Related]
2. Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.
Katreddy RR; Bollu LR; Su F; Xian N; Srivastava S; Thomas R; Dai Y; Wu B; Xu Y; Rea MA; Briggs JM; Zhang Q; Lu X; Huang G; Weihua Z
Oncogenesis; 2018 Jan; 7(1):5. PubMed ID: 29358623
[TBL] [Abstract][Full Text] [Related]
3. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.
Thomas R; Srivastava S; Katreddy RR; Sobieski J; Weihua Z
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121829
[TBL] [Abstract][Full Text] [Related]
4. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Ren J; Bollu LR; Su F; Gao G; Xu L; Huang WC; Hung MC; Weihua Z
Prostate; 2013 Sep; 73(13):1453-61. PubMed ID: 23765757
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
6. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
9. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor targeting in cancer.
Mendelsohn J; Baselga J
Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
Shelton JG; Steelman LS; Abrams SL; Bertrand FE; Franklin RA; McMahon M; McCubrey JA
Expert Opin Ther Targets; 2005 Oct; 9(5):1009-30. PubMed ID: 16185155
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
13. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
14. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.
Dokala A; Thakur SS
Oncogene; 2017 Apr; 36(17):2337-2344. PubMed ID: 27775071
[TBL] [Abstract][Full Text] [Related]
15. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
16. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
Ghosh S; Liu XP; Zheng Y; Uckun FM
Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
Mitchell RA; Luwor RB; Burgess AW
Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone alters epidermal growth factor receptor binding affinity via activation of extracellular signal-regulated kinases in 3T3-F442A cells.
Huang Y; Chang Y; Wang X; Jiang J; Frank SJ
Endocrinology; 2004 Jul; 145(7):3297-306. PubMed ID: 15070853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
